Transaction details
Martine Rothblatt, Chairperson and Chief Executive Officer of United Therapeutics Corporation (NASDAQ: UTHR), completed the sale of 9,500 shares of the company’s common stock on March 20, 2026, according to a recently filed SEC Form 4. The disposals were carried out under a pre-arranged 10b5-1 trading plan and brought in proceeds ranging from $520.343 to $529.0775 per share, totaling $4,987,386.
Option exercise
The same filing records that Rothblatt simultaneously exercised stock options to acquire 9,500 shares at an exercise price of $146.03 per share, representing a total outlay of $1,387,285. Both the option exercise and the subsequent sales are disclosed together in the Form 4.
Post-transaction holdings
After these transactions, Rothblatt’s direct ownership in United Therapeutics stands at 40,513 shares. The filing also specifies indirect holdings through multiple trusts and family ownership: 166 shares are held by a spouse, and several trusts hold 324,518; 258,117; 45,596; and 10,962 shares, respectively.
Company developments reported alongside the filing
United Therapeutics disclosed a series of corporate updates in proximity to the Form 4: the company published results from its phase 3 TETON-2 study, evaluating nebulized Tyvaso in idiopathic pulmonary fibrosis, in the New England Journal of Medicine. The study met its primary endpoint, showing a statistically significant improvement in lung function versus placebo.
In addition, United Therapeutics announced a $2 billion stock repurchase program. Of that amount, $1.5 billion is earmarked for accelerated share repurchase agreements with Citibank, with the remaining $500 million available for additional repurchases at the company’s discretion over the coming year.
Analyst reactions noted in the filing
Citing analyst commentary, the filing highlights that Cantor Fitzgerald raised its price target for United Therapeutics to $625 while maintaining an Overweight rating. TD Cowen reiterated a Buy rating with a $575 price target, signaling continued analyst confidence in the company’s franchise.
Context and available research tools
The Form 4 filing and the company announcements were published alongside references to analytical resources that provide additional insight into United Therapeutics’ financial profile. Those resources note a financial health score labeled as "GREAT" and offer expanded valuation metrics and analyst coverage for subscribers.
What this filing shows
The SEC filing records an insider’s simultaneous exercise of stock options and sale of the same number of shares executed under a pre-arranged trading plan, and it is filed with detailed ownership breakdowns. The company’s public announcements include trial results, a significant repurchase authorization, and recent analyst target adjustments.